BioCentury
ARTICLE | Company News

Protein Sciences, Liomont deal

September 8, 2014 7:00 AM UTC

Protein Sciences granted Liomont exclusive rights to manufacture and commercialize Protein Sciences' Flublok seasonal influenza vaccine and Panblok pandemic influenza vaccine in Mexico. Liomont is responsible for obtaining regulatory approval in the country; Protein Sciences said Liomont plans to submit a regulatory application as soon as possible. Liomont will initially sell Flublok manufactured by Protein Sciences, which is eligible for "significant" licensing and milestone payments, plus double-digit royalties. Liomont also received a right of first negotiation to expand the deal to include other Latin American countries. Protein Sciences declined to disclose terms, and Liomont could not be reached. ...